EIKO LIFESCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.96 INR | +3.71% |
|
+4.15% | -18.89% |
| 31/05 | Eiko Lifesciences Forms New Limited Liability Partnership | MT |
| 13/05 | Eiko LifeSciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 187.2 | 217.9 | 38.77 | 302.5 | 403.3 | 635.6 |
| Enterprise Value (EV) 1 | 196.6 | 230.5 | 50 | 255.4 | 447.4 | 630 |
| P/E ratio | 77.8 x | -49 x | -2.03 x | 49.3 x | 53.9 x | 83.1 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 7.7 x | 5.08 x | 0.37 x | 2.52 x | 1.59 x | 3.47 x |
| EV / Revenue | 8.09 x | 5.38 x | 0.48 x | 2.13 x | 1.76 x | 3.44 x |
| EV / EBITDA | 51.7 x | -34.4 x | -1.11 x | 44.5 x | 34 x | 66 x |
| EV / FCF | - | 11,93,52,275 x | 21,45,327 x | -40,13,820 x | -54,29,070 x | 15,60,14,186 x |
| FCF Yield | - | 0% | 0% | -0% | -0% | 0% |
| Price to Book | 3.37 x | 4.43 x | 1.32 x | 2.42 x | 1.41 x | 2.16 x |
| Nbr of stocks (in thousands) | 3,820 | 3,820 | 3,820 | 3,820 | 8,316 | 8,316 |
| Reference price 2 | 49.00 | 57.05 | 10.15 | 79.20 | 48.50 | 76.43 |
| Announcement Date | 12/08/18 | 05/09/19 | 08/09/20 | 02/06/22 | 02/06/22 | 30/08/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Maart | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 24.3 | 42.86 | 104.1 | 119.9 | 254.1 | 183.2 |
| EBITDA 1 | 3.801 | -6.708 | -45.13 | 5.737 | 13.16 | 9.545 |
| EBIT 1 | 3.59 | -8.419 | -47.06 | 5.121 | 7.533 | 3.217 |
| Operating Margin | 14.77% | -19.64% | -45.2% | 4.27% | 2.96% | 1.76% |
| Earnings before Tax (EBT) 1 | 2.458 | -9.978 | -49.34 | 8.327 | 9.42 | 10.26 |
| Net income 1 | 1.963 | -4.445 | -19.06 | 6.143 | 7.057 | 7.688 |
| Net margin | 8.08% | -10.37% | -18.31% | 5.12% | 2.78% | 4.2% |
| EPS 2 | 0.6300 | -1.164 | -4.990 | 1.608 | 0.9000 | 0.9200 |
| Free Cash Flow | - | 1.931 | 23.31 | -63.62 | -82.42 | 4.038 |
| FCF margin | - | 4.5% | 22.39% | -53.06% | -32.43% | 2.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 42.31% |
| FCF Conversion (Net income) | - | - | - | - | - | 52.53% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/08/18 | 05/09/19 | 08/09/20 | 02/06/22 | 02/06/22 | 30/08/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 9.43 | 12.5 | 11.2 | - | 44.1 | - |
| Net Cash position 1 | - | - | - | 47.2 | - | 5.59 |
| Leverage (Debt/EBITDA) | 2.482 x | -1.867 x | -0.2487 x | - | 3.352 x | - |
| Free Cash Flow | - | 1.93 | 23.3 | -63.6 | -82.4 | 4.04 |
| ROE (net income / shareholders' equity) | 4.47% | -14.8% | -122% | 9.01% | 3.43% | 2.65% |
| ROA (Net income/ Total Assets) | 3.06% | -5.19% | -27.5% | 2.23% | 1.83% | 0.61% |
| Assets 1 | 64.16 | 85.57 | 69.21 | 275.1 | 386 | 1,261 |
| Book Value Per Share 2 | 14.60 | 12.90 | 7.710 | 32.70 | 34.40 | 35.40 |
| Cash Flow per Share 2 | 2.100 | 0.3000 | 0.0600 | 10.60 | 0.2600 | 0.7400 |
| Capex | - | 2.02 | 2.33 | - | 1.55 | 2.25 |
| Capex / Sales | - | 4.7% | 2.23% | - | 0.61% | 1.23% |
| Announcement Date | 12/08/18 | 05/09/19 | 08/09/20 | 02/06/22 | 02/06/22 | 30/08/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -18.89% | 86.29L | |
| -1.05% | 7.43TCr | |
| -0.76% | 4.69TCr | |
| +6.80% | 3.44TCr | |
| +9.37% | 1.81TCr | |
| +12.81% | 1.19TCr | |
| -3.01% | 1.04TCr | |
| -20.72% | 1.03TCr | |
| -1.35% | 903.76Cr | |
| -11.01% | 783.85Cr |
- Stock Market
- Equities
- NIDL Stock
- Financials Eiko LifeSciences Limited
